They identified three variants of the HLA-E–binding Env371–379 peptide through bioinformatics and peptide-binding assays and generated an HLA-E–restricted ImmTAV with picomolar affinity that redirected polyclonal T cells to efficiently kill HBV-associated hepatocellular carcinoma cells. This evidence concerns the gene HLA-E and hepatocellular carcinoma.